Navamedic: Launches treatment device for refractory depression
Oslo, 28 October 2016 – Navamedic ASA (OSE: NAVA), today announced an exclusive agreement with the Danish company, Re5 ApS, for Nordic distribution of Re5-NTS®, an innovative, non-invasive treatment device based on patented Danish technology, for patients with refractory depression.
Navamedic